DUBLIN--(BUSINESS WIRE)--The "Sepsis Diagnostics Market by Technology, Product, Method, Test Type, Pathogen, End-User - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
The global sepsis diagnostic market is projected to reach USD 613.9 Million by 2023 from USD 396.6 Million in 2018, at a CAGR of 9.1% during the forecast period.
Factors such as rising prevalence of sepsis across the globe, increasing geriatric population, growing government initiatives for creating sepsis awareness, and high incidence of hospital-acquired infections are expected to drive the demand for sepsis diagnosis during the study period.
On the basis of technology, the market is segmented into microbiology, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. In 2017, the microbiology segment accounted for the largest share of the sepsis diagnostic market.
On the basis of products, the global sepsis diagnostics market is segmented into blood culture media, assays & reagents, instruments, and software. The blood culture media segment is estimated to command the largest share of the global sepsis diagnostics market in 2018.
On the basis of methods, the sepsis diagnostic market is categorized into two segments, namely, conventional diagnostics and automated diagnostics. The automated diagnostics segment is expected to grow at the highest CAGR from 2018 to 2023.
On the basis of test type, the sepsis diagnostics market is further segmented into laboratory tests and point-of-care tests. The laboratory tests segment is estimated to account for the largest share of the sepsis diagnostic market in 2018.
Key Topics Covered
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Sepsis Diagnostics Market, By Technology
7 Sepsis Diagnostics Market, By Product
8 Sepsis Diagnostics Market, By Method
9 Sepsis Diagnostics Market, By Pathogen
10 Sepsis Diagnostics Market, By Test Type
11 Sepsis Diagnostics Market, By End User
12 Sepsis Diagnostics Market, By Region
13 Competitive Landscape
14 Company Profiles
- Axis-Shield Diagnostics
- Becton, Dickinson, and Company (BD)
- EKF Diagnostics
- Mitsubishi Chemical Europe
- Response Biomedical
- Roche Diagnostics (A Subsidiary of F. Hoffmann-LA Roche Ltd.)
- T2 Biosystems
- Thermo Fisher Scientific
For more information about this report visit https://www.researchandmarkets.com/research/35z255/global_sepsis?w=4